Agoda Spotlights Unique Asian Airports Redefining the Layover Experience
SINGAPORE, Oct. 20, 2025 /PRNewswire/ -- Digital travel platform Agoda has unveiled a list of five airports in Asia that transform layovers into memorable experiences. These airports offer more than just transit, with attractions that cater to both...
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
MILESEEY GenePro G1 Named to TIME's "The Best Inventions of 2025: Special Mentions"
The first "GPS + Laser" hybrid rangefinder redefining how golfers see and play the game. CITY OF INDUSTRY, Calif., Oct. 20, 2025 /PRNewswire/ -- MILESEEY Golf proudly announces that its groundbreaking hybrid rangefinder, the GenePro G1, has been...
Chengdu CATANIA's Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- A news report from CNS: Recently, a wave of discerning homebuyers from different cities has been converging on Chengdu CATANIA. International elites from New York, London, Tokyo, Singapore, Hong Kong,...
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian...
Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025
HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it will report its unaudited...